Cargando…
scAAV-Mediated Gene Transfer of Interleukin 1-Receptor Antagonist to Synovium and Articular Cartilage in Large Mammalian Joints
With the long-term goal of developing a gene-based treatment for osteoarthritis (OA), we performed studies to evaluate the equine joint as a model for AAV-mediated gene transfer to large, weight-bearing human joints. A self-complementary AAV2 vector containing the coding regions for human interleuki...
Autores principales: | Watson, Rachael S., Broome, Ted A., Levings, Padraic P., Rice, Bret L., Kay, Jesse D., Smith, Andrew D., Gouze, Elvire, Gouze, Jean-Noel, Dacanay, E. Anthony, Hauswirth, William W., Nickerson, David M., Dark, Michael J., Colahan, Patrick T., Ghivizzani, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577988/ https://www.ncbi.nlm.nih.gov/pubmed/23151520 http://dx.doi.org/10.1038/gt.2012.81 |
Ejemplares similares
-
Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1β
por: Gouze, Jean-Noël, et al.
Publicado: (2006) -
Optimal Inhibition of Choroidal Neovascularization by scAAV2 with VMD2 Promoter-driven Active Rap1a in the RPE
por: Wang, Haibo, et al.
Publicado: (2019) -
Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
por: Dehay, Benjamin, et al.
Publicado: (2012) -
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
por: MacLachlan, Timothy K., et al.
Publicado: (2017) -
Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020)